Ovarian Cancer Drugs Market Trends, Size, Growth by 2030

[Research Report] The ovarian cancer drugs market size is projected to grow from US$ 2.1 billion in 2022 to US$ 3.8 billion by 2030; the market is estimated to record a CAGR of 7.7% during 2022–2030.

Market Insights and Analyst View:

The rising incidence of ovarian cancer propels the ovarian cancer drugs market growth. However, product recalls due to adverse effects impede the market growth.

Growth Drivers:

Rising Incidence of Ovarian Cancer Propels Demand for Therapeutic Options

Ovarian cancer is the seventh most common cancer among women and the third most common gynecological malignancy, after cervical cancer and endometrial (uterine) cancers, respectively. According to the World Ovarian Cancer Coalition report, 324,000 women are diagnosed with ovarian cancer, and 207,000 women die of the disease annually. Further, the majority of patients with ovarian cancer are diagnosed with an advanced-stage (locally advanced or metastatic) condition as there is no public health screening program available for the early detection of ovarian cancer. Therefore, the rising incidence of ovarian cancer propels the demand for effective therapeutic options. The first-line therapy with a combination of debulking surgery and platinum-based chemotherapy is standard care for women newly diagnosed with advanced ovarian cancer. Also, therapeutic options such as approved PARP inhibitors, olaparib, rucaparib, and niraparib are the breakthrough options for the management of newly diagnosed ovarian cancer. The use of PARP inhibitors in the management of advanced ovarian cancer has also emerged as an effective therapeutic option to improve clinical outcomes. These inhibitors provide long-term efficacy and progression-free survival (PFS) in the newly diagnosed cases, following a complete response (CR) to the first, second, and third platinum-based chemotherapy.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Ovarian Cancer Drugs Market: Strategic Insights

Market Size Value in	US$ 2.1 billion in 2022
Market Size Value by	US$ 3.8 billion by 2030
Growth rate	CAGR of 7.7% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The ovarian cancer drugs market analysis has been carried out by considering the following segments: type, drug class, and distribution channel.

Segmental Analysis:

By type, the market is segmented into epithelial ovarian cancer, germ cell ovarian cancer, and stromal tumors. The epithelial ovarian cancer segment held the largest ovarian cancer drugs market share in 2022; the same segment is anticipated to register the highest CAGR of 8.2% during the forecast period. According to the Cancer Research UK report, epithelial ovarian cancer is the most common type of ovarian cancer. For example, nearly 90 out of 100 tumors of the ovary (90%) are epithelial tumors. Patients with aggressive, late-stage ovarian cancer have limited treatment options available in the market. In November 2022, the Food and Drug Administration (FDA) announced approval for "mirvetuximab soravtansine-gynx," manufactured by Elahere ImmunoGen, Inc. for adult patients suffering from epithelial ovarian cancer. The physician-recommended dose of this drug candidate for epithelial ovarian cancer treatment is 6 mg/kg, administered once every three weeks as an IV infusion. In January 2024, the FDA announced approval for fast-track designation (FTD) for "RC88," a mesothelin-targeting antibody-drug conjugate (ADC) for the treatment of patients with recurrent epithelial ovarian cancer. Thus, the rising number of drug approvals is propelling the ovarian cancer drugs market for the epithelial ovarian cancer segment.

Ovarian Cancer Drugs Market Trends

Combination Drug Therapy

Several medical research institutes are developing novel combination drugs to treat ovarian cancers.  In September 2023, researchers at the Royal Marsden announced a new drug combination therapy that proves effective in patients living with advanced ovarian cancer. The researchers tested combination drug therapy for its effect on low-grade serous ovarian cancer (LGSOC), a rare form of ovarian cancer with a poor response rate to treatments. The RAMP-201 clinical trial was conducted by combining the avutometinib drug with defactinib to investigate their synergistic therapeutic effect in patients suffering from LGSOC. The interim clinical trial results reveal that 45% of the patients treated with the drug combination saw their tumors shrink significantly. Such satisfactory clinical results with combination therapy are almost twice as effective compared to trametinib, a targeted therapy drug available in England that has a response rate of only 26%. In January 2024, the FDA announced approval for the SH-105 combination drug for the treatment of patients with breast and ovarian cancer. Thus, combination drug therapies are emerging as new trends that are likely to boost the ovarian cancer drugs market growth in the coming years.

Regional Analysis:

The scope of the ovarian cancer drugs market report entails North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest ovarian cancer drugs market share. The market growth in this region is driven by the increasing number of product launches by top companies and the presence of key market players. The US is the largest contributor to the market in North America. The rising incidence of ovarian cancers among women compels companies and regulatory bodies to develop and approve, respectively, innovative drugs in this region. Also, the rising number of contract clinical research organizations (CROs) favors the growth of the ovarian cancer drugs market in North America.

Ovarian Cancer Drugs Market Report Scope

Industry Developments and Future Opportunities:

The ovarian cancer drugs market forecast can help stakeholders in this marketplace plan their growth strategies. A few strategic developments by leading players operating in the market are listed below:

• In November 2022, ImmunoGen won FDA approval for ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of adult patients resistant to platinum-resistant epithelial ovarian cancer. The ELAHERE is specifically approved for patients with FRα-positive platinum-resistant ovarian cancer, which is a challenging condition due to the availability of limited treatment options and poor clinical outcomes of the existing therapeutics.

Competitive Landscape and Key Companies:

Elli Lilly, AstraZeneca, GSK, Zielab, ImmunoGen (AbbVie), GeneTech (Roche), Vivesto, Allarity Therapeutics, Inc., Aeterna Zentaris, and Luye Pharma are among the prominent companies profiled in the ovarian cancer drugs market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide.